It specifies that by 2035, China expects to fully ensure the safety, efficacy and accessibility of drugs and medical devices, ...

From PBMs to abortion, there are plenty of health policy issues that will vie for the spotlight in 2025. For pharma marketers ...

A collaboration between Kennedy and the New Jersey senator could be helpful for furthering nutrition policy, and could be ...

Patient organisations and charities are at risk of aligning their interests with their corporate funders even when this doesn't benefit their members, according to a new study led by the University of ...

But Dr. Robert Califf, who leads the government’s regulation of health software at the Food and Drug Administration, says his agency cannot monitor all advanced AI tools without a doubling of his ...

Hospitals and health systems, by and large, are going into 2025 on better footing than they were a year ago, as financial and ...

The independent expert body tasked with making recommendations on whether new medications should receive government subsidies ...

Drugmakers in India may soon face stricter enforcement of quality standards. The revised Schedule M, which details ...

RG-6540 is under clinical development by F. Hoffmann-La Roche and currently in Phase I for Follicular Lymphoma.

The legislative rush provided another example of state lawmakers struggling to reach consensus on significant policy matters, ...

The company provides products such as antibiotics, neurology products, endocrinology systems products ... For a complete picture of KI-3106’s drug-specific PTSR and LoA scores, buy the report here.